|
| Home : ROSEN, LEADING AND LONGSTANDING INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - SPPI |
|
Sep 20
2021 |
ROSEN, LEADING AND LONGSTANDING INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - SPPI |
|
NEW YORK, Sept. 19, 2021 /PRNewswire/ -- WHY: New York, N.Y., September 19, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021, inclusive (the "Class... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/rosen-leading-and-longstanding-investor-counsel-encourages-spectrum-pharmaceuticals-inc-investors-with-losses-exceeding-100k-to-secure-counsel-before-important-deadline-in-securities-class-action--sppi-30137995 |
| |
|
Related News
|
» USD 39.76 Billion Growth expected in "Display Market" by 2025 | Sourcing and Procurement Report | SpendEdge
» RYBREVANT® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
|
|
|
